摘要
目的:探讨云南省富源籍非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变率、突变特征及不同突变类型的分布特征,为该地区NSCLC的临床个体化靶向治疗提供依据。方法:选择2018年1月至2020年8月云南省富源县人民医院行EGFR检测的328例富源籍NSCLC患者,收集患者性别、年龄、民族、病理类型和EGFR检测结果等临床资料并进行统计分析。结果:NSCLC患者EGFR突变率40.55%(133/328)。女性患者EGFR突变率高于男性(P<0.01);随年龄增长,EGFR突变率呈下降趋势,≤60岁年龄组患者EGFR突变率高于>60岁年龄组(P=0.014);少数民族患者EGFR突变率与汉族相比差异无统计学意义(P=0.789);无吸烟史患者EGFR突变率高于有吸烟史患者(P<0.01);腺癌EGFR突变率高于鳞状细胞癌(P=0.002);Ⅰ~Ⅱ期患者EGFR突变率高于Ⅲ~Ⅳ期患者(P=0.013);组织标本检测突变率高于外周血检测(P=0.009)。328例患者中,EGFR单点突变率24.70%(81/328),复合突变率15.85%(52/328);常见突变率17.07%(56/328),稀有突变率23.48%(77/328)。突变率前5位的突变类型分别为L858R(10.06%)、G719X+S768I(7.32%)、19-Del(7.01%)、G719X+L861Q(6.40%)、G719X(4.21%)。133例EGFR突变患者中,稀有突变患者比例为57.89%(77/133),高于常见患者突变比例[42.11%(56/133)]。结论:富源地区女性、腺癌、无吸烟史和年轻NSCLC患者EGFR突变率较高,且稀有突变率较高。
Objective To investigate the epidermal growth factor receptor(EGFR)mutation rate,mutation characteristics and distribution characteristics of different mutation types in patients with non-small cell lung cancer(NSCLC)in Fuyang of Yunnan province,to provide the clinical individualized targeted therapy of NSCLC in this region.Methods A total of 328 NSCLC patients whose native place were Fuyuan and who underwent EGFR test in Fuyuan County People's Hospital in Yunnan Province from January 2018 to August 2020 were selected,and their clinical data such as gender,age,ethnicity,pathological type and the results of EGFR test were collected for statistical analysis.Results The EGFR mutation rate of NSCLC patients was 40.55%(133/328).The EGFR mutation rate of female patients was higher than that of males(P<0.01).The EGFR mutation rate showed a downward trend with age,the EGFR mutation rate of patients≤60 years old was higher than that of patients>60 years old(P=0.014).The EGFR mutation rate in ethnic minority was not statistically different from Han nationality(P=0.789).The EGFR mutation rate of patients without smoking history was higher than that of patients with smoking history(P<0.01).Patients with adenocarcinoma had a higher EGFR mutation rate than squamous cell carcinoma(P=0.002).The EGFR mutation rate in patients with stageⅠ-Ⅱwere higher than that in patents with stageⅢ-Ⅳ(P=0.013).The EGFR mutation rate in tissue samples were higher than that in peripheral blood samples(P=0.009).In 328 patients the EGFR single-point mutation rate was 24.70%(81/328),and the compound mutation rate was 15.85%(52/328);the common mutation rate was 17.07%(56/328),and the rare mutation rate was 23.48%(77/328).The top 5 mutation types were L858R(10.06%),G719X+S768I(7.32%),19-Del(7.01%),G719X+L861Q(6.40%),and G719X(4.21%).In 133 patients with EGFR mutation,the proportion of patients with rare mutation[57.89%(77/133)]was higher than the proportion of patients with common mutation[42.11%(56/133)].Conclusion The EGFR mutation rates of
作者
荀祥翰
雷青
张祥武
郭姜艳
李磊
刘东旭
戴友德
李银
万良红
李艳丽
张娟
林艳苹
Xun Xianghan;Lei Qing;Zhang Xiangwu;Guo Jiangyan;Li Lei;Liu Dongxu;Dai Youde;Li Yin;Wan Lianghong;Li Yanli;Zhang Juan;Lin Yanping(Department of Thoracic Surgery,Fuyuan County People's Hospital in Yunnan Province,Fuyuan 655500,China;Department of Thoracic Surgery,Yunnan Cancer Hospital,Kunming 650118,China;Department of Pathology,Yunnan Cancer Hospital,Kunming 650118,China;Department of Science and Education,Fuyuan County People's Hospital in Yunnan Province,Fuyuan 655500,China;Office of Yunnan Cancer Center,Yunnan Cancer Hospital,Kunming 650118,China)
出处
《肿瘤研究与临床》
CAS
2021年第7期499-503,共5页
Cancer Research and Clinic
基金
云南省应用基础研究重点项目(2017FA037)。
关键词
癌
非小细胞肺
受体
表皮生长因子
突变
分子靶向治疗
Carcinoma,non-small-cell lung
Receptor,epidermal growth factor
Mutation
Molecular targeted therapy
